Harmeet Kaur MD, Presenter: Nothing to Disclose

Evelyne Madeline Loyer MD, Abstract Co-Author: Nothing to Disclose

Chusilp Charnsangavej MD, Abstract Co-Author: Consultant, Novartis AG

Haesun Choi MD, Abstract Co-Author: Consultant, Novartis AG

1) To review the traditional response evaluation criteria for solid tumors (e.g RECIST), 2) To introduce the new concept of response evaluation of solid tumors based on our experience of gastrointestinal stromal tumor (GIST) and colorectal metastasis (CRM) 3) To discuss its potential application in other solid tumors ie breast, HCC etc.

Size-based traditional response evaluation of solid tumors has limitations particularly with targeted agents. Newly proposed CT parameters based on changes in morphology and degree of enhancement in GIST and CRM have shown a significant correlation with pathologic response and progression free survival. We review : Traditional response criteria New CT response criteria in GIST, CRM with pathological and clinical correlate Potential application of new concept in RCC, HCC etc.

Newly proposed CT response criteria are simple and reproducible in assessing tumor response and show significant correlation with the clinical outcome. The potential application of this concept in other tumors such as breast, HCC, RCC and cholangiocarcinoma also shows significant promise.

Kaur, H, Loyer, E, Charnsangavej, C, Choi, H, New Paradigm for Response Evaluation of Solid Tumors in the Era of Targeted Therapy: Comparison with Traditional Size-based Response Critera.  Radiological Society of North America 2011 Scientific Assembly and Annual Meeting, November 26 - December 2, 2011 ,Chicago IL. http://archive.rsna.org/2011/11004489.html